AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|
24.8 C
New York
Saturday, July 18, 2026

Tag: Sex

THCA Flower for Sale: Exhale Wellness Expands Online Availability with New Exotic Indoor Strains for 2026

THCA flower for sale at Exhale Wellness: shop new exotic indoor-grown strains for 2026, lab-tested and Farm Bill-compliant. Buy premium hemp buds online.

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

THCA Pre-Rolls 2026: Exhale Wellness Reports Rising Demand for Ready-to-Smoke Hemp Pre-Rolls as Buyers Move Away From Loose Flower

Exhale Wellness 2026 survey: 70% of THCA pre-roll buyers cite convenience as shoppers move from loose flower to lab-tested, ready-to-smoke hemp pre-rolls.

ACRC Global Surrogacy Celebrates Pride in Irvine and Los Angeles, Supporting LGBTQIA+ Families on Their Path to Parenthood

Leading Reproductive Agency Highlights Specialized LGBTQIA+ Family-Building Programs, Including Gestational Surrogacy, IVF Coordination, and Safe HIV Surrogacy via Advanced Sperm WashingLos Angeles, June 22,...

Lovense Calls for “Closing the Gap Takes Two” Amid a Decades-Old Orgasm Gap

LOS ANGELES, June 17, 2026 /PRNewswire/ -- If you've ever finished sex and thought "that was fine" while knowing, somewhere deeper, that it wasn't...

Adam & Eve Marks National Sex Education Month With Survey On Bedroom Confidence

HILLSBOROUGH, N.C., June 16, 2026 /PRNewswire/ -- In honor of National Sex Education Month and as part of its expanding commitment to sexual health...

Landsbankinn hf.: Útgáfa í norskum krónum

Landsbankinn lauk í dag sölu á víkjandi forgangsbréfum (e. senior non-preferred bond) með breytilegum vöxtum að fjárhæð 250 milljónir norskra króna. Skuldabréfin eru til sex ára og með heimild til innköllunar að fimm árum liðnum (6NC5). Útgáfukjör miðast við 125 punkta álag á þriggja mánaða millibankavexti í norskum krónum.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

PPMW launches summer Spill the Tea ambassadorship for Black Women

WASHINGTON, June 8, 2026 /PRNewswire/ -- In May, Planned Parenthood of Metropolitan Washington, DC launched the most recent cohort of its Spill the Tea...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 7, 2026 /CNW/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSex